Thymagen (Thymogen)

Immune Regulation, Inflammation Control, and Healthy Aging

The thymus plays a central role in immune health, yet it begins to decline shortly after puberty. As thymic activity decreases, the body produces fewer naïve T cells, immune signaling becomes less coordinated, and recovery from illness or stress slows. Thymagen (also known as Thymogen; international nonproprietary name: Oglufanide) is a synthetic dipeptide composed of L-glutamic acid and L-tryptophan (Glu-Trp, or EW) that has been extensively studied for its role in immune regulation and age-related immune decline. Thymagen was originally isolated from the thymic polypeptide complex Thymalin via reversed- phase high-performance liquid chromatography (RP-HPLC) and was subsequently synthesized. It was developed by Russian scientists including Vladimir Khavinson and Vyacheslav Morozov at the Saint Petersburg Institute of Bioregulation and Gerontology. The synthesized dipeptide was registered as the pharmaceutical drug Thymogen in the USSR in 1990 and has been used clinically in Russia and CIS countries for over three decades. Rather than acting as an immune stimulant, Thymagen functions as a bioregulator—supporting balance, coordination, and restoration of immune signaling at the cellular and genetic level. Its molecular weight is 333.34 Da, its molecular formula is C16H19N3O5, and its CAS number is 38101-59-6. It is available in multiple dosage forms including injectable solution, intranasal spray, and topical cream. Thymagen is not FDA-approved in the United States. It is available as a research chemical for laboratory and investigational purposes.

How It Works

Thymagen works through multiple mechanisms to restore and regulate immune function, influence gene expression, and support cellular repair. As a dipeptide bioregulator, it acts upstream in immune signaling pathways, influencing how immune cells behave rather than forcing a specific response.

Epigenetic Gene Regulation

A distinguishing feature of Thymagen is its ability to interact with DNA and nuclear proteins at the epigenetic level. Research by Khavinson et al. has demonstrated that the Glu-Trp dipeptide reacts specifically with the AACG nucleotide sequence in DNA. This binding is believed to transform silent heterochromatin into active euchromatin, increasing the availability of relevant genes for transcription. This gene-level interaction influences the synthesis of heat shock proteins, cytokines, fibrinolysis system components, and proteins involved in immune cell differentiation, proliferation, and apoptosis.

T Cell Maturation and Differentiation

One of Thymagen’s primary research-backed roles is its effect on T lymphocyte differentiation and maturation:

• Stimulates proliferation and differentiation of T lymphocyte precursors into mature

immunocompetent cells

• Normalizes the ratio of T-helper cells to T-suppressor cells
• Stimulates expression of CD4 and CD5 molecules on thymic cells, facilitating

differentiation toward T-helper phenotypes

• Enhances T cell recognition of peptide-MHC complexes, improving immune surveillance

Cyclic Nucleotide Modulation

Research by Demidov et al. demonstrated that Thymagen modulates the balance between cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in lymphocytes. Thymagen increases the concentration of cAMP in T lymphocyte precursors and modulates the activity of phosphodiesterase enzymes responsible for cyclic nucleotide catabolism. This cAMP/cGMP signaling balance is fundamental to immune cell activation, differentiation, and the coordination of immune responses.

Innate Immune Enhancement

Thymagen strengthens nonspecific resistance through multiple pathways:

• Activates phagocytic functions of neutrophils and monocytes/macrophages
• Stimulates interferon production (interferonogenesis)
• Enhances natural killer cell function, particularly at low doses
• Activates innate immune responses through TLR/RLR (Toll-like receptor/RIG-I-like

receptor) signaling pathways

Cytokine Modulation and Anti-Inflammatory Effects

Thymagen regulates cytokine production, including reducing excess proinflammatory mediators such as TNF-alpha and IL-6 in experimental models. It possesses anti-mediator properties, moderating inflammatory signaling rather than suppressing immune function. This regulatory action is particularly relevant in aging or stressed biological systems where immune responses become inefficient or dysregulated.

Cellular Repair and Regeneration

Thymagen has been associated with enhanced cellular repair mechanisms. In organotypic culture studies, it increased the growth zone index of spleen tissue explants by 20 to 50 percent and stimulated proliferation while reducing apoptosis by 29 to 42 percent. The peptide also accumulates in epithelial cells of the respiratory tract, contributing to its bronchoprotective effects.

Benefits

Immune System Modulation

Thymagen’s primary benefit is restoring and normalizing immune function:

• Normalizes T cell differentiation, proliferation, and the ratio of T-helper to T-suppressor

cells

• Restores immune parameters in states of immunodeficiency caused by illness, stress,

radiation, or chemotherapy

• Enhances phagocytic activity and natural killer cell function
• Supports appropriate immune activation without excessive inflammatory signaling

Infectious Disease Support

Thymagen has demonstrated clinical utility in various infectious disease contexts:

• Restored immune reactivity in complex therapy of viral hepatitis, tuberculosis, and

influenza

• Improved outcomes in experimental infections caused by Yersinia enterocolitica
• Used in acute respiratory viral infections, papillomatosis, and sepsis
• Improved general condition and ensured faster biochemical and immune restoration in

intestinal amebiasis, typhoid fever, and acute dysentery

• Preliminary COVID-19 research showed potential for normalizing lymphocyte counts

and monocyte populations

Anti-Aging and Geroprotective Effects

Thymagen has demonstrated significant geroprotective properties:

• In a landmark animal study, rats treated with L-Glu-L-Trp for 12 months showed a

significantly lower aging rate (Gompertz alpha: 0.0041 vs. 0.0071)

• Maximum lifespan of the longest-surviving 10 percent of treated rats was 1,048 days

versus 949 days in controls

• Contributes to restoration of immune system functions and reduced mortality in elderly

populations

• Influences telomere length regulation in PHA-stimulated lymphocytes and affects aging-

related gene expression

Cancer Prevention Support

Thymagen has shown promise in experimental cancer prevention:

• Total spontaneous tumor incidence was 1.5 times lower in treated rats
• Malignant tumor incidence was 1.7 times lower
• Hematopoietic malignancies (leukemias and lymphomas) were 3.4 times lower
• Decreased chemically induced tumor incidence by 12 percent and reduced tumor

multiplicity 1.7 times

Post-Surgical and Recovery Support

A double-blind, randomized, placebo-controlled study demonstrated that preoperative use of Thymagen in elderly patients after removal of solid tumors restored structural and functional immune parameters and led to a statistically significant decrease in postoperative complications and a reduction in the postoperative period.

Respiratory and Dermatological Support

The intranasal spray form has been used for prevention and treatment of acute and chronic nonspecific lung diseases, including infectious, inflammatory, and allergic bronchopulmonary conditions. The cream form has been used for atopic dermatitis, chronic eczema, chronic pyoderma, and wound healing following mechanical, thermal, and chemical skin injuries.

Cardiovascular Protection

Studies by Filippova et al. in cardiac cells demonstrated that Thymagen may mitigate damage to cardiomyocytes in ischemic conditions through a mechanism independent of opiate receptors and calcium channel blockade, suggesting a unique cytoprotective action.

What the Science Shows

Thymagen has extensive research supporting its use in immune modulation, geroprotection, and clinical medicine.

Aging and Carcinogenesis Study (Anisimov/Popovich et al., 2003) In this landmark study, 76 female outbred rats were randomized into two groups. Treated rats received 5 micrograms of L-Glu-L-Trp subcutaneously five times per week for 12 months. Key findings:

• Aging rate (Gompertz alpha) was significantly reduced: 0.0041 in treated rats versus

0.0071 in controls

• Maximum lifespan of the 10 percent longest survivors was 1,048 ± 21.1 days versus 949

± 16.1 days in controls (P < 0.001)

• Six out of 44 treated rats survived beyond the maximum lifespan of the control group
• Total tumor incidence was 1.5 times lower (P < 0.01)
• Malignant tumor incidence was 1.7 times lower (P < 0.01)
• Leukemias and lymphomas were 3.4 times lower (P < 0.02)

Molecular Mechanism Review (Khavinson et al., 2021) A comprehensive review published in Biology Bulletin Reviews detailed the molecular mechanism of action:

• Confirmed that the EW dipeptide binds to specific DNA sequences and histone proteins
• Demonstrated regulation of gene expression related to heat shock proteins, cytokines, and

immune cell processes

• Showed that Thymagen normalizes coagulation and fibrinolytic activity of blood plasma

proteins

• Confirmed geroprotective properties including a 1.5-fold decrease in spontaneous tumors

TLR/RLR Signaling Study (Sokolova et al., 2019) Research demonstrated Thymagen’s ability to activate innate immune responses through TLR/RLR signaling pathways, enhancing cellular capacity to detect and respond to viral pathogens.

Post-Surgical Study (Smirnov et al., 2011) A double-blind, randomized, placebo-controlled study in elderly patients after solid tumor removal demonstrated restored immune parameters, a statistically significant decrease in postoperative complications, and a reduced postoperative recovery period.

COVID-19 Research (Linkova et al., 2023) A study in the International Journal of Molecular Sciences examined the influence of the KE and EW dipeptides on gene expression and protein synthesis involved in COVID-19 pathogenesis, demonstrating their role in regulating immune responses during coronavirus infection.

Cardioprotection Study (Filippova et al., 1997) Cardiac cell studies demonstrated that Thymagen mitigated ischemic damage through a mechanism independent of opiate receptors and calcium channel blockade.

Anti-Tumor Studies (Bespalov et al., 1990; Anisimov et al., 1992) Bespalov et al. demonstrated that Thymagen decreased chemically induced tumor incidence by 12 percent and reduced tumor multiplicity by 1.7 times. Anisimov et al. found protective effects against radiation-induced carcinogenesis in rat models.

Dosing Protocol

Standard Protocol (Injectable) Dose: 100 mcg (0.1 mg) per injection Route: Subcutaneous or intramuscular injection

Frequency: Once daily

Cycle Length: 3 to 10 days Course Total: 300 to 1,000 mcg per course Repeat: As needed based on clinical response

By Application

Immune Support and Optimization:

• 100 mcg daily for 5 to 10 days via subcutaneous or intramuscular injection
• Can be repeated seasonally or as needed
• For prevention, shorter 3- to 5-day courses may be used

Respiratory Infection Prevention (Intranasal):

• 25 mcg per nostril (50 mcg total) via intranasal spray, twice daily
• Treatment duration: 10 days; preventive duration: 3 to 5 days

Dermatological Applications (Topical):

• 0.01 to 0.05 percent Thymagen cream applied to affected areas once to twice daily for 10

to 20 days Anti-Aging Protocol:

• 100 mcg daily for 10 days, repeated every 3 to 6 months
• May be combined with other bioregulators such as Epitalon or Thymalin

Administration

Thymagen is available in three dosage forms: injectable solution (subcutaneous or intramuscular), intranasal spray, and topical cream. The injectable form provides systemic immune modulation, while the spray and cream offer localized delivery for respiratory and dermatological conditions respectively.

Draw Volumes by Vial Size

20 mg Vial with 2 mL Bacteriostatic Water (10 mg/mL Concentration) Dose Volume Units on Syringe 50 mcg (0.05 mg) 0.005 mL 0.5 units 100 mcg (0.1 mg) 0.01 mL 1 unit 200 mcg (0.2 mg) 0.02 mL 2 units 300 mcg (0.3 mg) 0.03 mL 3 units

500 mcg (0.5 mg) 0.05 mL 5 units Note: At a standard dose of 100 mcg daily for 10 days, one 20 mg vial provides approximately 200 doses, making it extremely economical.

Reconstitution

Materials Needed:

• Thymagen vial (lyophilized powder)
• Bacteriostatic water
• Sterile syringe for reconstitution
• Alcohol swabs

Instructions: 1. Wipe the vial stopper and bacteriostatic water vial with alcohol swabs. 2. Draw 2 mL of bacteriostatic water. 3. Insert the needle through the rubber stopper at an angle. 4. Let the water trickle slowly down the inside wall of the vial. 5. Do not inject directly onto the powder or shake vigorously. 6. Gently swirl until fully dissolved. 7. The solution should be clear. If cloudy or containing particles, do not use.

Side Effects

Thymagen has an excellent safety profile with over three decades of clinical use. As a short synthetic dipeptide, it is rapidly metabolized into its constituent natural amino acids (L-glutamic acid and L-tryptophan), reducing the risk of accumulation or long-term toxicity. Common (Generally Mild):

• Mild injection site redness or discomfort (injectable form)
• Temporary nasal irritation (intranasal spray)
• Mild transient fatigue in the first few days

Rare:

• Allergic reactions (extremely rare)
• Mild nausea

Safety Profile: In animal toxicology studies, no toxic effects were observed at doses up to 10,000 mcg/kg (at least 10 to 1,000 times the recommended therapeutic dose). Thymagen does not alter hormones,

overstimulate the immune system, or create dependence. It has been used safely in combination with antibiotics, antiviral drugs, chemotherapy agents, and radiotherapy.

Contraindications and Precautions

Do Not Use If:

• You have a known hypersensitivity to Thymagen or any component
• You are taking immunosuppressant medications deliberately (such as organ transplant

recipients) Use Caution With:

• Pregnancy or breastfeeding (safety has not been established)
• Active autoimmune conditions (consult a physician first)
• Pediatric use under age 14 (consult physician for younger patients)

Drug Interactions: Thymagen has been safely combined with many treatments including antibiotics, antiviral medications, chemotherapy agents, and other peptide bioregulators. Caution is advised when combining with other immunomodulators to avoid overstimulation or suppression. Consult a qualified healthcare provider before use.

Comparison

Compound Mechanism Best For Thymagen (EW) Epigenetic regulation, Precise immune regulation, cAMP/cGMP modulation, respiratory support, TLR/RLR activation dermatological use Thymalin Multi-peptide thymic extract Broad immune restoration, anti- (EW, KE, EDP), broad epigenetic aging, post-illness recovery effects Thymosin Alpha-1 TLR-2/TLR-9 activation, single Chronic viral infections, vaccine 28-amino-acid peptide enhancement, acute immune support Epithalamin Pineal peptide, telomerase Neuroendocrine regulation, activation, melatonin regulation telomere lengthening, anti-aging BPC-157 Growth factors, angiogenesis, Tissue healing, injury recovery, nitric oxide modulation gut repair

KPV NF-kB inhibition, cytokine Anti-inflammatory support, gut suppression inflammation

Thymagen vs. Thymalin

Thymagen is actually one of the active components of Thymalin. It is the EW (Glu-Trp) dipeptide isolated from the larger Thymalin polypeptide complex. As a single dipeptide, Thymagen offers more targeted and stable immune signaling modulation, while Thymalin provides broader thymic support by influencing a wider range of pathways simultaneously through its three key peptides (EW, KE, EDP). The two are sometimes used together in research protocols.

Thymagen vs. Thymosin Alpha-1

Thymagen is a 2-amino-acid dipeptide (333 Da) that works primarily through epigenetic gene regulation and cAMP/cGMP modulation. Thymosin Alpha-1 is a 28-amino-acid peptide (3,108 Da) that works through TLR-2 and TLR-9 activation on dendritic cells. Thymosin Alpha-1 has more extensive clinical trial data for chronic viral infections and is approved in over 35 countries. Thymagen has a broader range of dosage forms and more data on geroprotective effects and cancer prevention.

Success Tips

Timing for Maximum Benefit

Consider using Thymagen:

• Before cold and flu season as a preventive immune primer
• Before travel to areas with infectious disease risk
• Before or after surgery to support immune recovery
• As part of an anti-aging or longevity regimen

Combine with Good Immune Fundamentals

Thymagen works best alongside:

• Adequate sleep (7 to 9 hours per night)
• Stress management
• Balanced nutrition with adequate protein
• Regular moderate exercise
• Zinc supplementation (zinc is a cofactor for thymulin, essential for T cell maturation)
• Vitamin D optimization

Consider Synergistic Combinations

• Thymalin for broad-spectrum thymic immune restoration alongside Thymagen’s targeted

regulation

• Epithalamin or Epitalon for synergistic geroprotective effects
• Thymosin Alpha-1 for complementary immune support (different mechanisms)

Monitor Your Response

• Frequency and severity of infections
• Duration of illness when sick
• Energy levels and overall vitality
• Skin condition and wound healing (if using topical form)
• Consider baseline and follow-up lab work including immune panels and inflammatory

markers

Storage and Handling

Before Reconstitution:

• Store lyophilized vials at 36 to 46°F (2 to 8°C)
• For long-term storage, may be stored at -4°F (-20°C)
• Protect from light and minimize moisture exposure

After Reconstitution:

• Refrigerate at 36 to 46°F
• Use within 14 to 30 days when reconstituted with bacteriostatic water
• Do not freeze after reconstitution
• Keep the stopper clean; maintain sterile handling
• If the solution becomes cloudy or contains particles, discard it

Legal Status

United States: Thymagen is not FDA-approved. It is available as a research chemical. Russia and CIS Countries: Thymogen was registered as a pharmaceutical in the USSR in 1990 (Registration Certificate No. P N002408/01). It has been used clinically for over three decades in injectable, intranasal, and topical forms for immune dysfunction, viral and bacterial infections, and wound healing. International: Thymagen is primarily available through Russian pharmaceutical channels and as a research peptide internationally.

Product Source

Thymagen (Thymogen) is available for research purposes only. When sourcing research-grade Thymagen, ensure the supplier provides third-party testing, certificates of analysis (COA), and proper documentation of purity (typically ≥98%). Always verify the legitimacy and quality standards of any peptide supplier.

Frequently Asked Questions

How is Thymagen different from Thymalin? Thymagen is the EW (Glu-Trp) dipeptide that was isolated from the larger Thymalin polypeptide complex. As a single dipeptide, Thymagen offers more targeted immune regulation, while Thymalin contains multiple active fragments (EW, KE, EDP) that influence a broader range of pathways. How long until I notice effects? Immune markers can begin improving within the 3- to 10-day treatment cycle. For anti-aging benefits, effects accumulate over repeated cycles and are best measured through lab work over months. Why is the dose so small compared to other peptides? Thymagen works at the epigenetic level, binding directly to DNA sequences and histone proteins. This upstream regulatory mechanism requires very small amounts to initiate changes in gene expression that persist well beyond the treatment period. Can Thymagen be combined with other peptides? Yes. Thymagen has been safely combined with other bioregulators and standard medical therapies. It is commonly used alongside Thymalin, Epithalamin, and antiviral or antibacterial treatments. Specific combinations should be discussed with a healthcare provider. What forms is Thymagen available in? In Russia, Thymogen is available as injectable ampoules, intranasal spray, and topical cream. As a research peptide internationally, it is typically available as lyophilized powder for reconstitution.

References

1. Popovich IG, Voitenkov BO, Anisimov VN, et al. Immunomodulatory synthetic dipeptide L- Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. 2003;4(5):297-309. https://pubmed.ncbi.nlm.nih.gov/11707921/ 2. Khavinson VKh, Linkova NS, Chalisova NI, Ivko OM. The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biol Bull Rev. 2021;11(4):367- 375. https://pmc.ncbi.nlm.nih.gov/articles/PMC8365293/

3. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997;19(9-10):501-505. 4. Demidov SV, et al. Effect of thymagen, thymalin and vilosen on cAMP and cGMP levels in spleen lymphocytes. Ukr Biokhim Zh. 1991;63(4):104-106. 5. Sokolova TM, et al. Signaling TLR/RLR-mechanisms of immunomodulating action of thymogen. Russ J Infect Immun. 2019;9(1):60-66. 6. Filippova OV, et al. The effect of thymogen on the heart in ischemia and reperfusion. Eksp Klin Farmakol. 1997;60(3):27-29. 7. Bespalov VG, et al. Inhibiting effect of thymogen on tumor development induced by N- nitrososarcosine ethyl ester in rats. Eksp Onkol. 1990;12(6):40-43. 8. Linkova N, et al. The influence of KE and EW dipeptides on gene expression involved in COVID-19 pathogenesis. Int J Mol Sci. 2023;24(17):13377. 9. D’Angiulli A, et al. Peptides regulating proliferative activity and inflammatory pathways in the THP-1 cell line. Int J Mol Sci. 2022;23(7):3607. 10. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuroendocrinol Lett. 2003;24(3-4):233-240. https://pubmed.ncbi.nlm.nih.gov/14523363/